APA (7th ed.) Citation

LM, W., W, H., FH, G., AA, P., MP, W., CF, M., . . . EA, I. (2024). Burosumab vs conventional therapy in children with X-linked hypophosphatemia: Results of the open-label, phase 3 extension period. JBMR plus, 8(1), ziad001. https://doi.org/10.1093/jbmrpl/ziad001

Chicago Style (17th ed.) Citation

LM, Ward, et al. "Burosumab Vs Conventional Therapy in Children with X-linked Hypophosphatemia: Results of the Open-label, Phase 3 Extension Period." JBMR Plus 8, no. 1 (2024): ziad001. https://doi.org/10.1093/jbmrpl/ziad001.

MLA (9th ed.) Citation

LM, Ward, et al. "Burosumab Vs Conventional Therapy in Children with X-linked Hypophosphatemia: Results of the Open-label, Phase 3 Extension Period." JBMR Plus, vol. 8, no. 1, 2024, p. ziad001, https://doi.org/10.1093/jbmrpl/ziad001.